Sol-gel technologies screens first patient for sgt-610 phase 3 study

Ness ziona, israel, nov. 30, 2023 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl) (“sol-gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, twyneo® and epsolay®, today announced that it has begun phase 3 testing of sgt-610 (patidegib gel, 2%) for gorlin syndrome with the first patient screened. sgt-610 is a new topical hedgehog inhibitor being developed to prevent the new basal cell carcinoma (bcc) lesions in patients with gorlin syndrome that is expected to have an improved safety profile compared to oral hedgehog inhibitors. patidegib was acquired by sol-gel from pellepharm and is currently the only therapy in development to prevent the development of new bcc lesions in gorlin syndrome patients.
SLGL Ratings Summary
SLGL Quant Ranking